IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
MILTENYI-MB-CART2019-1-DLBCL
Phase II
OPEN TO ACCRUAL
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
NOVARTIS-YTB323A12101
Phase I
OPEN TO ACCRUAL
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL